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Abstract
Background: Cardiovascular disease (CVD) susceptibility differs between men and women and varies with ethnicity. This
variability is not entirely explained by conventional CVD risk factors. We examined differences in circulating levels of 47
novel protein markers of CVD in 2561 men and women of African-American (AA) and non-Hispanic White (NHW) ethnicity,
enrolled at geographically distinct sites.
Methodology/Principal Findings: Participants (1,324 AAs, mean age 63.5 y, 71% women; 1,237 NHWs, mean age 58.9 y,
57% women) belonged to sibships ascertained on the basis of hypertension. Solid-phase immunoassays and
immunoturbidometric, clot-based, chromogenic, and electrophoretic assays were used to measure the 47 protein markers
in plasma or serum. Marker levels were log transformed and outliers were adjusted to within 4 SD. To identify markers
independently associated with sex or ethnicity, we employed multivariable regression analyses that adjusted for
conventional risk factors, prior history of CVD, medication use and lifestyle factors (physical activity, alcohol consumption
and education). Generalized estimating equations were used to correct for intrafamilial correlations. After adjustment for
the above covariates, female sex was associated with higher levels of 29 markers and lower levels of 6 markers. Female sex
was independently associated with higher levels of several inflammatory markers as well as lipoproteins, adipokines,
natriuretic peptides, vasoconstrictor peptides and markers of calcification and thrombosis. AA ethnicity was associated with
higher levels of 19 markers and lower levels of 6 markers, including higher levels of several inflammatory makers, higher
leptin and lower adiponectin levels, lower levels of vasodilator-natriuretic peptides, higher levels of vasoconstrictor-
antidiuretic peptides and markers of calcification and thrombosis.
Conclusions/Significance: Plasma levels of several novel protein markers of CVD differ significantly in the context of sex and
ethnicity. These results have implications for individualized CVD risk assessment.
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Introduction
Algorithms based on several established risk factors are used in
the clinical setting for stratifying the risk of cardiovascular disease
(CVD) in asymptomatic individuals [1,2,3,4]. However, these risk-
stratification algorithms are limited in their ability to discriminate
which individuals will suffer adverse cardiovascular events [5,6].
Several methods have been proposed to improve specificity of
cardiovascular risk stratification [7,8,9]. Advances in our knowl-
edge of the pathophysiology of arteriosclerotic vascular disease
have highlighted its complex etiology and led to the proposal of a
‘‘multimarker approach’’ for risk stratification [9]. Although novel
biomarkers hold promise for refining CVD risk stratification and
formulating tailored strategies to improve quality-of-life and
reduce mortality [10,11,12], reliable and reproducible assays of
circulating protein markers are often unavailable [13]. Further-
more, the effects of sex and ethnicity on the plasma levels of key
candidate protein markers have not been fully described.
The Mayo Vascular Proteomics Program was funded by the
National Heart, Lung and Blood Institute to investigate multi-
marker approaches for early detection of CVD. Protein markers
(n=47, see Table 1 for abbreviations) were selected from
pathways of inflammation, lipoprotein metabolism, adipocyte
metabolism, hemodynamic stress, calcification and thrombosis.
Markers were selected based on basic science, observational and
clinical studies suggesting the roles of these markers in arterio-
sclerosis and in mediating end-organ damage in the context of
hypertension. Uniplex and multiplex assays were used to measure
the 47 markers in stored blood samples of 1324 African-American
(AA) and 1237 non-Hispanic white (NHW) participants. In this
report, we describe the associations of sex and ethnicity with
circulating levels of these 47 protein markers.
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Study Population
Subjects included participants in the Genetic Epidemiology
Network of Arteriopathy (GENOA) study, a multicenter com-
munity-based study to identify genes influencing blood pressure
(BP) and development of target organ damage due to hyperten-
sion [11,14]. These cohorts are enriched for hypertension and
thereby suitable for identifying markers associated with subclin-
ical vascular disease. The AA participants were recruited from
Jackson in Hinds County, Mississippi, while the NHW partici-
pants were recruited from Rochester in Olmsted County, MN.
The Jackson, MS cohort of the Atherosclerosis Risk in
Communities study [15], originally a probability sample of
persons with driver’s licenses, was used to ascertain AA sibships.
The sampling frame of the Rochester GENOA cohort was the
Mayo Clinic diagnostic index and medical record linkage system
of the Rochester Epidemiology Project [16]. It was used to
identify NHW residents of Olmsted County, MN, diagnosed with
essential hypertension before age 60. If the eligible proband had
at least one sibling with hypertension, all available full biologic
siblings of the index hypertensive, including normotensive
siblings, were invited to participate in interviews, physical
examinations, and phlebotomy at their respective centers. The
only exclusionary criterion at enrollment at either center was the
presence of a secondary cause of hypertension (such as
documented renal artery stenosis or advanced renal insufficiency)
in the index sibs.
In Phase I of the study, sibships with at least 2 individuals
diagnosed with essential hypertension prior to the age of 60 years
were enrolled in Jackson, MS (AA subjects, n=1854) and
Rochester, MN (NHW subjects, n=1583). Between December 1,
Table 1. Protein marker abbreviations.
CRP, C-reactive protein SAA, serum amyloid A ICAM, Intercellular adhesion
molecule
VCAM, vascular cell adhesion
molecule
IL-6, interleukin 6
IL-18, interleukin 18 TNFRI, tumor necrosis
factor receptor-1
TNFRII, tumor necrosis
factor receptor-2
MCP-1, monocyte chemotactic
protein-1
Hsp27, heat shock protein 27
MPO, myeloperoxidase RAGE, receptor for
advanced glycation
endproducts
MMP-2, matrix
metalloproteinase-2
MMP-9, matrix
metalloproteinase-9
TIMP-1, tissue inhibitor
of metalloproteinases-1
TIMP-2, tissue inhibitor
of metalloproteinases-2
ApoA-I, apolipoprotein
A-I
ApoB, apolipoprotein B ApoC-III, apolipoprotein C-III ApoE, apolipoprotein E
LDL, low-density lipoprotein Lp(a), lipoprotein (a) Ox-LDL, oxidized
low-density lipoprotein
Lp-PLA2, lipoprotein-associated
phospholipase A2
NT-proBNP, N-terminal
pro-brain natriuretic peptide
MR-proANP, midregional
pro-atrial natriuretic peptide
CT-proAVP, C-terminal
pro-arginine vasopressin
MR-proADM, midregional
pro-adrenomedullin
CT-proET, C-terminal
pro-endothelin
OPN, osteopontin
OPG, osteoprotegerin ONN, osteonectin OCN, osteocalcin vWF, von Willebrand Factor ATIII, antithrombin III
doi:10.1371/journal.pone.0009065.t001
Table 2. Participant characteristics and ethnic differences.
Women (n=1638) Men (n=923)
N AA (n=936) NHW (n=702) P AA (n=388) NHW (n=535) P
Age, years 2561 63.369.4 58.4610.3 ,.0001 64.369.0 59.5610.0 ,.0001
BMI, kg/m
2 2557 32.567.0 30.867.1 ,.0001 29.264.9 30.765.1 ,.0001
Total cholesterol, mg/dL 2561 205.9641.0 202.8634.9 0.1078 191.9641.0 190.0632.7 0.4335
HDL cholesterol, mg/dL 2561 61.0618.1 57.4615.4 ,.0001 49.3615.6 44.5611.4 ,.0001
Systolic BP, mm Hg 2559 139.5621.2 131.7617.9 ,.0001 136.3620.1 130.3615.9 ,.0001
Diastolic BP, mm Hg 2559 78.2610.6 72.869.2 ,.0001 81.1610.9 75.369.1 ,.0001
Ever smoker, % 2651 289 (30.9) 284 (40.5) 0.0001 250 (64.4) 326 (60.9) 0.2787
Diabetes, % 2651 282 (30.1) 92 (13.1) ,.0001 109 (28.1) 93 (17.4) 0.0001
Previous history of MI or stroke 2651 78 (8.3) 37 (5.3) 0.0164 53 (13.7) 55 (10.3) 0.1149
Statin use, % 2651 170 (18.2) 165 (23.5) 0.0080 76 (19.6) 197 (36.8) ,.0001
Aspirin use, % 2651 287 (30.7) 243 (34.6) 0.0906 149 (38.4) 267 (49.9) 0.0005
Physical activity score 2561 9.663.1 12.864.9 ,.0001 10.264.1 14.165.6 ,.0001
Alcohol (oz)/month 2548 0.863.9 3.166.0 ,.0001 3.267.9 9.1614.1 ,.0001
Education, years 2561 12.363.4 13.462.2 ,.0001 11.664.2 13.562.6 ,.0001
eGFR, mg/dL 2561 75.3619.8 63.7613.6 ,.0001 74.5619.9 65.4613.7 ,.0001
AA, African American; NHW, non-Hispanic white; BMI, body mass index; HDL, high-density lipoprotein; BP, blood pressure; eGFR, estimated glomerular filtration rate; MI,
myocardial infarction.
doi:10.1371/journal.pone.0009065.t002
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Women (n=1638) Men (n=923)
N AA (n=936) NHW (n=702) P AA (n=388) NHW (n=535) P
Inflammation
CRP, mg/L 2550 3.59*** 3.33*** 0.1528 2.91 2.10 ,.0001
SAA, mg/mL 2113 22.63*** 22.77*** 0.9013 16.91 15.94 0.3587
ICAM, ng/mL 2003 274.48* 284.74 0.0334 260.41 279.91 0.0015
VCAM, ng/mL 2496 570.21 687.62 ,.0001 558.63 670.71 ,.0001
IL-6, pg/mL 2220 7.98 7.30 0.0053 7.90 7.78 0.7422
IL-18, pg/mL 2151 60.49 69.58** ,.0001 61.58 75.70 ,.0001
TNFRI, pg/mL 2129 1027.66 1266.95 ,.0001 1046.58 1302.81 ,.0001
TNFRII, pg/mL 2222 1731.16 1857.16 0.0012 1751.27 1889.10 0.0029
MCP-1, pg/mL 2153 978.56 859.33* ,.0001 980.77 901.42 0.0012
E-selectin, ng/mL 2225 68.85 69.36* 0.6689 70.69 72.19 0.3334
P-selectin, ng/mL 2186 30.09** 27.66*** 0.0016 32.80 32.87 0.9512
Hsp27, ng/mL 2206 1726.27 1484.84** 0.0041 1721.46 1274.73 ,.0001
MPO, ng/mL 2379 36.56 28.54** ,.0001 34.70 25.08 ,.0001
RAGE, pg/mL 2167 437.96*** 597.53 ,.0001 359.32 560.34 ,.0001
MMP-2, ng/mL 2221 1807.08 1693.05 0.0015 1808.72 1705.78 0.0142
MMP-9, ng/mL 1794 29.18 34.66 ,.0001 30.01 36.16 ,.0001
TIMP-1, ng/mL 2219 68.47*** 83.92*** ,.0001 75.18 92.97 ,.0001
TIMP-2, ng/mL 2120 156.29 148.24 0.0013 152.29 146.87 0.0556
Lipoprotein metabolism
ApoA-I, mg/dL 2391 164.85*** 169.53*** 0.0358 137.75 139.30 0.5150
ApoB, mg/dL 2330 92.22 97.61 0.0001 89.77 97.96 ,.0001
ApoC-III, mg/dL 2261 14.02*** 18.19*** ,.0001 12.98 16.32 ,.0001
ApoE, mg/dL 2260 5.26*** 5.14*** 0.2681 4.68 4.79 0.3739
LDL size, nm 2561 269.34*** 270.60*** ,.0001 267.89 269.28 ,.0001
Lp(a), mg/dL 2561 46.83*** 15.76* ,.0001 35.80 13.85 ,.0001
Ox-LDL, U/L 2275 62.31 65.69 0.0024 63.48 65.94 0.0882
Lp-PLA2 mass, ng/mL 2294 204.34* 242.36** ,.0001 211.39 253.29 ,.0001
Lp-PLA2 activity, mol/min/mL 2227 119.30*** 129.67*** ,.0001 137.11 154.89 ,.0001
Adipocyte metabolism
Leptin, ng/mL 2288 26.51*** 22.46*** ,.0001 9.62 8.81 0.0337
Adiponectin, mg/mL 2424 10.11*** 13.07*** ,.0001 7.65 9.56 ,.0001
Resistin, ng/mL 2308 3.62** 3.76*** 0.1519 3.24 3.39 0.1975
Hemodynamics
NT-proBNP, pg/mL 2043 79.74 127.57*** ,.0001 84.77 107.28 ,.0001
MR-proANP, pmol/L 2548 60.53* 71.16*** ,.0001 55.82 58.60 0.2267
CT-proAVP, pmol/L 2511 7.25*** 4.72*** ,.0001 9.54 6.55 ,.0001
MR-proADM, nmol/L 2501 0.53*** 0.60*** ,.0001 0.49 0.54 ,.0001
CT-proET, pmol/L 2366 42.15* 40.31 0.0892 44.91 42.24 0.0297
Calcification
OPN, pg/mL 1872 25.61* 18.81*** ,.0001 28.04 23.37 0.0002
OPG, pg/mL 2297 307.44*** 265.88*** ,.0001 284.20 238.56 ,.0001
ONN, pg/mL 2232 945.24 895.78 0.0041 925.35 915.86 0.6769
OCN, pg/mL 2193 14.57* 11.32*** ,.0001 13.57 12.90 0.1351
Thrombosis
Factor II, % activity 2341 110.67*** 105.01*** ,.0001 103.12 98.20 0.0022
Factor V, % activity 2405 102.40 93.77 ,.0001 100.00 93.03 ,.0001
Factor VII, % activity 2424 114.65*** 122.45*** 0.0001 100.84 105.50 0.0462
Factor VIII, % activity 2363 148.48** 128.95* ,.0001 139.13 122.43 ,.0001
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returned for a second study visit and underwent physical
examination, provided blood samples and underwent character-
ization of subclinical markers of arteriosclerosis. Blood was
collected by venipuncture after an overnight fast and processed
using standardized protocols at each collection site. Blood was
centrifuged for 10 min at 4uC, aliquoted in 0.5–1 mL volumes of
sodium-citrate plasma, EDTA plasma, and serum and stored at
280uC within 2 h of venipuncture. Aliquots of AA samples
frozen to 280uC were shipped to Rochester, MN overnight on
dry ice. Samples were visually inspected for evidence of thawing
and then stored at 280uC. For protein measurements, samples
were thawed on ice and aliquoted into bar-coded Eppendorf
tubes. The new sample aliquots were re-frozen to 280uCu n t i l
time of testing at which point they were thawed on ice again.
Thus, samples from each collection site were exposed to identical
numbers of freeze-thaw cycles for a given assay, ensuring that
differential sample handling would not contribute to any
subsequently noted ethnic differences in protein levels. The
study was approved by the Institutional Review Boards of the
University of Mississippi Medical Center, Jackson, MS, and
Mayo Clinic, Rochester, MN, and participants gave informed
consent.
Conventional Risk Factors
Standardized protocols were used by trained study coordinators
in all examinations. Height was measured by stadiometer and
weight by electronic balance to calculate body mass index (BMI)
(kg/m
2). Resting systolic and diastolic BP levels were measured
with a random zero sphygmomanometer in the right arm. The
diagnosis of hypertension was based on either BP measurements
(.140/90 mm Hg) or previous diagnosis of hypertension and
current treatment with anti-hypertensive medications. Diabetes
was considered present if a participant was receiving treatment
with insulin, oral agents, or had fasting serum glucose levels
$126 mg/dL. Information about the use of BP medications,
statins, and estrogen use was obtained from questionnaires
completed by the participants. Serum cholesterol, high-density
lipoprotein (HDL) cholesterol, glucose, and creatinine were
measured by standard enzymatic methods.
Lifestyle Variables
Information on three ‘lifestyle’ variables – physical activity,
alcohol consumption, and education – was obtained from a
questionnaire administered to the participants. We constructed a
physical activity scale using responses to questions on how many
hours per day of heavy activity, moderate activity, slight activity, and
sedentary activity the participant engaged in. Specifically, the
physical activity score was derived as follows: 2*heavy + moderate –
sedentary (hours). Alcohol intake was quantified as ounces of alcohol
per month and was estimated from the type and frequency of
beverage consumed. Education was recorded as years in school.
Measurement of Candidate Biomarkers
The 47 candidate protein markers of vascular disease were
measured in plasma (EDTA or citrate) or serum using solid-phase
immunoassays (n=32) and immunoturbidometric (n=7), clot-
based (n=5), chromogenic (n=2), and electrophoretic (n=1)
assays using commercially available reagents (Table S1). MR-
proADM, CT-proAVP, CT-proET, and MR-proANP were
measured as part of a research collaboration with BRAHMS
AG (Henningsdorf, Germany). Given the logistical difficulties of
measuring a large number of markers in 2561 participants, a
subset of markers were measured using multiplex assays; IL-6, IL-
18, P-selectin, RAGE, TNFRI, E-selectin, MCP-1, MMP-2,
MMP-9, TIMP-1, TIMP-2, TNFRII, and ICAM were measured
using a contracted service with SearchLight
TM Technologies
(Boston, MA). The markers of calcification (OPN, OPG, ONN,
OCN) were measured in the investigator’s laboratory using the
Meso Scale Discovery immunoassay platform (Gaithersburg, MD).
The remaining proteins were either measured in investigator’s
laboratory or the Mayo Immunochemical Core Laboratory
(Rochester, MN).
Technical Assay Performance
We evaluated intra- and inter-assay imprecision at a minimum
of one level for each analyte to assess technical assay performance
(please see supplementary Table S1). Precision data for MR-
proADM[17], CT-proAVP[18], CT-proET[19], and MR-
proANP[20] were derived from previous reports. For analytes
measured at Mayo, we prospectively determined intra-assay
imprecision (reported as coefficient of variation (CV)) by
measuring the candidate protein markers in blood samples from
volunteers in 10 parallel measurements, and inter-assay impreci-
sion (CV) by measuring the same samples across 10 assay runs. We
retrospectively determined precision for the assays performed by
SearchLight
TM based on data derived from a blinded, internal
plasma control sample. Due to plate-to-plate variations in protein
levels in the SearchLight data sets, we developed an algorithm to
reduce inter-plate variability; normalized data were used for
subsequent analyses [13].
Quality Control
Our quality control program included evaluation of intra-
assay imprecision between duplicate sample measurements and
Women (n=1638) Men (n=923)
N AA (n=936) NHW (n=702) P AA (n=388) NHW (n=535) P
vWF, IU/dL 2468 178.52* 147.92 ,.0001 169.99 145.41 ,.0001
D-dimer, ng/mL 2397 208.07* 181.12*** 0.0001 188.41 152.58 ,.0001
ATIII, % activity 2445 108.81*** 106.83 0.0056 105.62 105.53 0.9225
Fibrinogen, mg/dL 2552 363.16*** 313.93 ,.0001 342.38 313.30 ,.0001
AA, African American; NHW, non-Hispanic white; BMI, body mass index.
Geometric means were presented after adjusted by age and BMI, based on the log transformed value after winsorization and imputation.
*, **, *** indicate the significance levels for sex difference in each ethnic group are 0.05, 0.01, and 0.001, respectively.
doi:10.1371/journal.pone.0009065.t003
Table 3. Cont.
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measured protein levels in duplicate, except for Lp-PLA2 mass
and activity, for which only single measurements were made.
Sample measurements with CVs .20% were either retested or
excluded from the dataset. Acceptable imprecision of measure-
ments from the SearchLight
TM platform was set at ,30% due
to performance limitations; mean values of samples with CVs
.30% were replaced with the singlet value closest to the plate
median because retesting was not feasible. We monitored inter-
assay imprecision by measuring 1–3 quality control materials as
part of each assay run, and we interpreted the results using a
multi-rule approach (13s and 22s Westgard rules) [21]. These
rules reject all data included in an assay run if any level of QC
material was three standard deviations (SD) above or below the
target value or if 2 or more levels were 2 SD beyond the target
value in the same direction. Only the 13s rule was applied to the
OPN assay due to a problem with the second level of QC
material. With the exceptiono fp r o t e i n sm e a s u r e do nt h e
SearchLight
TM platform, acceptable coefficient of variance
between inter-plate measurements was ,20% for all assays
and analyses were performed in real-time. Two levels of
SearchLight
TM controls and one normal serum control were
embedded randomly across study plates and evaluated retro-
spectively using a modified multi-rule approach as described
Table 4. Markers independently associated with female sex; multivariable regression analyses.
African American, n=1324 non-Hispanic White, n=1237
Protein marker b6SE P b6SE P
CRP, mg/L 0.24360.070 0.0005 0.30260.063 ,.0001
SAA, mg/mL 0.20560.067 0.0022 0.13060.061 0.0328
ICAM, ng/mL 0.09160.026 0.0005 0.06660.022 0.0022
P-selectin, ng/mL 20.02160.034 0.5288 20.09360.038 0.0144
Hsp27, ng/mL 0.02960.070 0.6758 0.17060.076 0.0252
MPO, ng/mL 0.06060.040 0.1327 0.14060.053 0.0079
RAGE, pg/mL 0.19160.038 ,.0001 0.08060.043 0.0625
TIMP-1, ng/mL 20.07460.025 0.0026 20.06060.025 0.0164
ApoA-I, mg/dL 0.15860.014 ,.0001 0.15460.016 ,.0001
ApoC-III, mg/dL 0.07660.025 0.0028 0.04860.023 0.0387
ApoE, mg/dL 0.15060.026 ,.0001 0.07260.023 0.0016
LDL size, nm 0.00360.001 0.0079 0.00160.001 0.3312
Lp(a), mg/dL 0.21960.068 0.0013 0.24660.080 0.0022
Lp-PLA2 mass, ng/mL 20.00760.019 0.7294 20.04560.021 0.0323
Lp-PLA2 activity, mol/min/mL 20.10760.019 ,.0001 20.13260.020 ,.0001
Leptin, ng/mL 0.98560.043 ,.0001 0.88060.037 ,.0001
Adiponectin, mg/mL 0.15160.039 0.0001 0.18860.032 ,.0001
Resistin, ng/mL 0.11360.038 0.0025 0.08360.032 0.0088
NT-proBNP, pg/mL 20.08860.050 0.0769 0.13660.044 0.0021
MR-proANP, pmol/L 0.02360.038 0.5414 0.10160.037 0.0062
CT-proAVP, pmol/L 20.23360.044 ,.0001 20.38160.048 ,.0001
MR-proADM, nmol/L 0.10160.019 ,.0001 0.12460.026 ,.0001
CT-proET, pmol/L 20.00160.026 0.9723 0.06660.029 0.0252
OPG, pg/mL 0.06160.025 0.0146 0.05960.024 0.0156
OPN, pg/mL 0.07060.023 0.0023 20.00760.026 0.7803
OCN, pg/mL 0.15560.037 ,.0001 20.07660.034 0.0264
Factor II, % activity 0.07360.017 ,.0001 0.06160.015 0.0001
Factor V, % activity 0.03460.016 0.0332 0.03560.015 0.0247
Factor VII, % activity 0.12360.023 ,.0001 0.12960.021 ,.0001
Factor VIII, % activity 0.06460.024 0.0081 0.02460.027 0.3690
vWF, IU/dL 0.07060.028 0.0127 20.00260.031 0.9363
D-dimer, ng/mL 0.11260.045 0.0124 0.18760.046 ,.0001
ATIII, % activity 0.03360.008 0.0001 0.02460.009 0.0059
Fibrinogen, mg/dL 0.08760.016 ,.0001 0.05360.019 0.0043
Protein marker levels were natural log-transformed and adjusted for age, BMI, smoking, hypertension, diabetes, myocardial infarction, stroke, total and HDL cholesterol,
eGFR, systolic blood pressure, medication use (aspirin, estrogen, statin), alcohol, physical activity, education; no total and HDL cholesterol adjustment was done for
ApoA-I, ApoB, ApoC-III, and ApoE.
doi:10.1371/journal.pone.0009065.t004
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either repeated or excluded from the data set.
Statistical Analysis
Circulating levels of markers were log transformed due to
skewed distribution and data beyond 4 SD were identified as
outliers and winsorized to the minimal or maximal value within 4
SD. Multiple imputation (stratified by ethnic group) using PROC
MI in SAS was applied to impute missing values for the protein
markers (range 0-29.9%; SAA 17.5%, ICAM 21.8%, IL-18
16.0%, TNFRI 16.9%, MCP-1 15.9%, RAGE 15.4%, NT-
proBNP 20.2%, MMP-9 29.9%, TIMP-2 17.2%, OPN 26.9%).
All analyses were performed in SAS 9.1.3 (SAS Institute Inc.,
Cary, NC).
Age- and BMI-adjusted geometric means of the 47 protein
markers were compared in men and women of the two ethnic
groups using the Wald chi-square test. We investigated whether
sex was independently associated with circulating levels of
biomarkers using multivariable regression analysis, after adjusting
for conventional cardiovascular risk factors (age, smoking,
hypertension, total cholesterol, HDL cholesterol, diabetes), history
of CVD, a measure of adiposity (BMI), medication use
(antihypertensives, statins, aspirin, and in women, estrogen),
lifestyle variables, and estimated glomerular filtration rate (eGFR).
Adjustment for total and HDL cholesterol was not performed for
the lipoproteins ApoA-I, ApoB, ApoC-III, and ApoE. Similar
multivariate regression analyses, stratified by sex, were used to
identify markers independently associated with ethnicity. Because
of sibships in the sample, population-averaged generalized
estimating equations[22] were used to account for the impact of
familial correlations on the relationships between independent and
dependent variables.
Results
Clinical characteristics of the study population are listed in
Table 2. AA were older, had higher BP levels, were more often
diabetic, had lower physical activity scores, and lower statin and
aspirin use. There were higher rates of smoking in AA men and
NHW women. The age and BMI-adjusted geometric means of the
protein markers in men and women, stratified by ethnicity, are
shown in Table 3.
After adjustment for age, BMI, conventional risk factors, prior
history of CVD, medication use, and lifestyle factors, female sex
was associated with higher levels of 29 markers and lower levels of
6 markers (Table 4, Figure 1). Differences were largely consistent
across the two ethnic groups and spanned all pathways studied.
Female sex was associated with higher levels of several
inflammatory biomarkers (CRP, SAA, ICAM, Hsp27, MPO and
RAGE), apolipoproteins (ApoA-I, ApoC-III, ApoE, Lp(a)), larger
LDL particle size, higher levels of adipokines (leptin, adiponectin
and resistin), vasodilator peptides (NT-proBNP in NHW, MR-
proANP and MR-proADM, vasoconstrictor peptide CT-proET in
NHW, calcification markers (OPG, ONN, and OCN (in AA)) and
thrombotic markers (Factors II, V, VII, and VIII, vWF, D-dimer,
ATIII and fibrinogen). Female sex was associated with lower levels
of inflammatory markers P-selectin and TIMP-1, Lp-PLA2 mass
and activity, vasoconstrictor peptide CT-proAVP and calcification
Figure 1. Association of female sex with circulating levels of protein markers. Multivariable regression analyses; markers independently
associated with female sex (graphical representation of Table 4, P,0.05, b6SE for 1 log change in a marker level is shown).
doi:10.1371/journal.pone.0009065.g001
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(b6SE=0.9960.04 in AA) and CRP (b6SE=0.3060.06 in
NHW) and the strongest inverse associations were with CT-
proAVP (b6SE=-0.3860.05 in NHW) and Lp-PLA2 activity
(b6SE=-0.1360.02 in NHW).
AA ethnicity was associated with higher levels of 19 markers and
lower levels of 6 markers after adjustment for age, BMI,
conventional risk factors, prior history of CVD, medication use,
and lifestyle factors (Table 5, Figure 2). Differences were largely
consistent in both men and women, and spanned all studied
pathways. AA ethnicity was associated with higher levels of
inflammatory biomarkers (CRP, MCP-1, P-selectin, Hsp27, MPO,
MMP-2 and TIMP-2), Lp(a), leptin and vasoconstrictor peptides
(CT-proAVP, CT-proET), markers of calcification (OPG and
OCN), and thrombosis (Factors II, V, and VIII, vWF, D-dimer,
fibrinogen). AA ethnicity was associated with lower levels of
several inflammatory markers (ICAM, VCAM, IL-18, TNFRI,
RAGE, MMP-9, TIMP-1), lipoproteins (ApoB, ApoC-III, LDL
size, Lp-PLA2 mass and activity), adiponectin and vasodilator
peptides (NT-proBNP, MR-proANP, MR-proADM). The stron-
gest positive association was for Lp(a) (b6SE=1.0860.10 in men),
although MPO and CT-proAVP both had strong associations as
well (b6SE=0.3260.06 and 0.4960.05, respectively in men).
The strongest inverse associations with AA ethnicity were RAGE
(b6SE=20.4260.05 in men), adiponectin (b6SE=20.3460.04
in men), and NT-proBNP (b6SE=20.4560.04 in women).
As an internal check of validity, we assessed the ability of the
protein markers to predict sex. We randomly split each cohort in
half to create a training and test population within each group.
The 47 markers predicted sex with 93% accuracy in both groups
(c-statistic=0.933 in AA and=0.931 in NHW) with little
degradation of performance between training and test samples.
In addition, we repeated analyses with outliers removed rather
than winsorized and found that our inferences did not change
(analyses not shown).
Discussion
It is becoming evident that for chronic, progressive diseases such
as arteriosclerosis, multiple biomarkers will be needed to improve
risk stratification, i.e. the ‘‘multimarker’’ approach. The value of
using more than one marker has been illustrated in several studies.
In the Atherosclerosis Risk in Communities study, patients in the
highest tertile of Lp-PLA2 mass level were not associated with
increased CV risk unless they also had elevated CRP levels [23]. In
another study, the incidence of coronary heart disease was highest
in the patients with both elevated CRP and D-dimer [24].
Zethelius et al [25]. found that 4 biomarkers from diverse etiologic
pathways provided significantly improved prediction of future CV
events compared to conventional risk factors in a cohort of elderly
men. In the present study, we highlighted sex and ethnic
differences in 47 candidate protein markers of CVD and our
results may help direct future individualized risk-assessment and
provide insights into pathophysiology.
Sex Differences in Markers
After adjustment for potential confounders, levels of the acute
phase reactants, CRP and SAA, adhesion molecule ICAM,
pattern recognition receptor RAGE and the osteoclast-inhibiting
cytokine OPG were higher in women, suggesting a pro-
inflammatory state with upregulation of adhesion molecules
[22-29]. There were also significant differences in the lipoprotein
markers between the sexes. It is known that women and men have
different baseline lipid profiles [26]. We found increased HDL-
component ApoA-I in women along with the VLDL-component
ApoC-III, Lp(a) and ApoE levels. There are known sex differences
in baseline HDL cholesterol levels and recent evidence suggests
lipoprotein markers have sex-specific relationships with subclinical
vascular disease (e.g. intima-media thickness) [27]. An analysis
from the Multi-Ethnic Study of Atherosclerosis study[28] com-
pared post-menopausal women to men and found serum estradiol
Table 5. Markers independently associated with African
American ethnicity; multivariable regression analyses.
Women, n=1638 Men, n=923
Protein marker b6SE P b6SE P
CRP, mg/L 0.1560.06 0.0167 0.2260.08 0.0048
ICAM, ng/mL 20.0760.02 0.0011 20.1060.02 ,.0001
VCAM, ng/mL 20.1960.02 ,.0001 20.2260.03 ,.0001
IL-18, pg/mL 20.1760.04 ,.0001 20.1960.05 0.0001
TNFRI, pg/mL 20.1260.03 0.0003 20.1760.04 ,.0001
MCP-1, pg/mL 0.1560.02 ,.0001 0.0660.03 0.0574
P-selectin, ng/mL 0.0860.03 0.0068 20.0160.04 0.8340
Hsp27, ng/mL 0.1760.06 0.0056 0.3260.08 0.0001
MPO, ng/mL 0.3060.05 ,.0001 0.3260.06 ,.0001
RAGE, pg/mL 20.2860.04 ,.0001 20.4260.05 ,.0001
MMP-2, ng/mL 0.0660.03 0.0134 0.0360.03 0.3286
MMP-9, ng/mL 20.1660.04 ,.0001 20.1660.05 0.0005
TIMP-1, ng/mL 20.1660.02 ,.0001 20.2260.03 ,.0001
TIMP-2, ng/mL 0.0560.02 0.0155 0.0160.02 0.7831
ApoB, mg/dL 20.0560.02 0.0024 20.0860.02 0.0006
ApoC-III, mg/dL 20.1760.02 ,.0001 20.1560.03 ,.0001
LDL size, nm 20.0160.001 ,.0001 20.0160.002 ,.0001
Lp(a), mg/dL 1.0860.08 ,.0001 1.0860.10 ,.0001
Lp-PLA2 mass, ng/mL 20.1860.02 ,.0001 20.2060.03 ,.0001
Lp-PLA2 activity, mol/min/mL 20.0960.02 ,.0001 20.1460.02 ,.0001
Leptin, ng/mL 0.2860.03 ,.0001 0.1560.05 0.0014
Adiponectin, mg/mL 20.2960.03 ,.0001 20.3460.04 ,.0001
NT-proBNP, pg/mL 20.4560.04 ,.0001 20.2960.05 ,.0001
MR-proANP, pmol/L 20.0860.03 0.0120 20.0960.05 0.0513
CT-proAVP, pmol/L 0.4760.04 ,.0001 0.4960.05 ,.0001
MR-proADM, nmol/L 20.0360.02 0.2273 20.0860.02 0.0011
CT-proET, pmol/L 0.0960.03 0.0017 0.1060.03 0.0010
OPN, pg/mL 0.2760.05 ,.0001 0.1260.06 0.0369
OPG, pg/mL 0.1560.02 ,.0001 0.1560.03 ,.0001
OCN, pg/mL 0.2260.03 ,.0001 0.0760.04 0.1056
Factor II, % activity 0.0660.01 ,.0001 0.0960.02 ,.0001
Factor V, % activity 0.0760.02 ,.0001 0.0860.02 0.0002
Factor VIII, % activity 0.1260.02 ,.0001 0.1360.03 ,.0001
vWF, IU/dL 0.1860.03 ,.0001 0.1860.04 ,.0001
D-dimer, ng/mL 0.1860.04 ,.0001 0.1160.05 0.0440
Fibrinogen, mg/dL 0.1560.02 ,.0001 0.0960.02 ,.0001
Protein marker levels were natural log-transformed, stratified by sex and
adjusted for age, BMI, smoking, hypertension, diabetes, myocardial infarction,
stroke, total and HDL cholesterol, eGFR, systolic blood pressure, medication
use (aspirin, estrogen, statin), alcohol, physical activity, education; no total
and HDL cholesterol adjustment was done for ApoA-I, ApoB, ApoC-III, and
ApoE.
doi:10.1371/journal.pone.0009065.t005
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Identifying differences between sexes in lipoprotein levels will help
clarify their roles in health and disease.
Circulating levels of the adipokines leptin and resistin were
higher in women than men, consistent with earlier reports [29,30].
These adipokines are associated with truncal obesity and glucose
intolerance and may contribute to increased activity of the nuclear
factor kappa-light-chain-enhancer of activated B-cells (NFkB)
pathway and subsequent cytokine production and upregulation of
cell adhesion molecules [31,32,33,34]. Consistent with previous
reports, levels of the insulin-sensitizing and cardioprotective
adipokine adiponectin were higher in women, possibly attenuating
some of the deleterious effects of higher leptin levels [35,36,37].
Higher leptin levels have been reported to be more strongly
associated with CVD in women than in men [38].
Significant sex differences were noted for plasma levels of the
hemodynamic markers. CT-proAVP was significantly lower in
women, possibly reflecting differences in hypothalamic downregu-
lation of vasopressin by estrogen [39]. In contrast, NHW women
had higher levels of the vasodilator natriuretic peptides NT-
proBNP and MR-proANP and the vasodilator peptide, MR-
proADM, suggestive of different baseline homeostatic set points
that may have future implications for tailored antihypertensive
pharmacotherapy. Higher natriuretic peptide levels have been
associated with lower free testosterone levels[40] and there is
significant extracardiac transcription of natriuretic peptides in the
ovaries and uterus, even after menopause [41]. Another potential
explanation is that women have lower plasma levels of renin,
known to be inversely associated with natriuretic peptide levels [42].
Plasma levels of markers of calcification, OPG, OPN (in AA)
and OCN (in AA) were higher in women than men. These
factors are known to increase with bone remodeling and after
‘‘tissue’’ injury such as myocardial infarction [43], coronary
artery disease[44] and osteoporosis[44]. We found higher OCN
l e v e l si nA Aw o m e nt h a ni nA Am e n ,b u tl o w e rl e v e l si nN H W
women than NHW men. Previously, investigators have found
lower plasma OCN levels in pre- vs. post-menopausal
women[45] and lower OCN levels in premenopausal women
compared to men[45], but higher OCN levels in postmeno-
pausal women compared to men. These differences and the
association of calcification markers with menopausal status point
to a role of the endogenous sex hormones in influencing
circulating OCN levels.
Factor II, V, and VII activities and levels of D-dimer and
fibrinogen were higher in women than men. Among AA, women
also had higher Factor VIII activity and increased levels of vWF
compared to men. As Factor VIII is stabilized by vWF, this may
reflect higher production or lesser degradation of vWF in AA
women [46]. Higher levels of these biomarkers have been
associated with increased CVD risk [47].
In summary, female sex was associated with higher levels of
inflammatory markers, insulin-resistance promoting adipokines
Figure 2. Association of African American ethnicity with circulating levels of protein markers. Multivariable regression analyses; markers
independently associated with African American ethnicity (graphical representation of Table 5, P,0.0, b6SE for 1 log change in a marker level is
shown).
doi:10.1371/journal.pone.0009065.g002
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and coagulation factor levels and activity, potentially contrib-
uting to higher CVD risk (Table 6). While women traditionally
have been considered to have overall lower CVD risk, in the
postmenopausal setting, risk catches up with that of men [48]. It
is unclear what contribution treatment differences vs. patho-
physiologic differences make to this transition, but some of this
‘‘catch up’’ may be due to alterations in etiologic pathways that
can be studied through circulating levels of protein markers. A
recent study[49] from the Women’s Health Initiative used 7
markers of inflammation and thrombosis to create a ‘‘Biomarker
Risk Score’’ which improved risk-stratification for ischemic
stroke, concluding that further investigation of multimarker
panels was needed.
Ethnic Differences
AA ethnicity was associated with higher levels of CRP and
MPO, two inflammatory markers associated with higher CVD risk
[50,51,52,53,54]. However, levels of several other markers in the
NFkB pathway were lower in AA, including the cell adhesion
molecules ICAM and VCAM, along with IL-18, TNFRI, and
RAGE. These findings suggest ethnic differences in regulation of
the NFkB pathway with potential diagnostic and therapeutic
implications [55]. There was no significant association between
AA ethnicity and levels of SAA, IL-6, E-selectin and TNFRII.
Differences in apolipoprotein levels between AA and NHW are
well known and thought to be mediated partly by genetic
polymorphisms [56,57,58]. In our study, AA subjects had
favorable levels of ApoC-III and Lp-PLA2 mass and activity, but
higher Lp(a) levels, highlighting differential hepatic processing and
metabolism [59]. Higher Lp-PLA2 activity has been related to
greater CVD risk[60] and lower Lp-PLA2 activity has been
reported in AA [60].
Leptin levels were higher and adiponectin levels were lower in
AA men and women than in their NHW counterparts, which may
contribute to glucose intolerance and metabolic syndrome in AA
individuals. Adiponectin levels are lower in AA youths than in
their NHW counterparts[61] and have been associated with
increased risk of diabetes even after adjustment for BMI, lifestyle
factors, preexisting CVD, and systolic BP [62], providing a
potential mechanism of increased susceptibility to diabetes and
higher CVD risk in AA. In addition, it has been proposed that
ethnic differences in the distribution of visceral vs. subcutaneous
fat may be mediated by adiponectin and these differences may also
contribute to increased CVD risk [63].
Among the hemodynamic markers, levels of the vasodilator,
natriuretic peptide precursors NT-proBNP and MR-proANP were
lower in AA whereas levels of the vasoconstrictive, antidiuretic
peptides CT-proAVP and CT-proET peptides were higher. This
may partially explain the clinical observations that AAs have a
‘‘salt retaining’’ phenotype and are more sensitive to vasopressin
inhibition [64]. It is unclear whether the lower natriuretic peptide
levels in AA in our study represent ethnic differences in the
response to hemodynamic stress or a relative ‘‘deficiency’’ in
baseline vasodilator natriuretic peptide levels. Our findings may
help explain the higher propensity of hypertensive AA for adverse
CVD events and may be useful in interpreting ethnicity-specific
biomarker panels for CVD risk stratification.
Three of the four markers of calcification were higher in AA
than in NHW participants. Emerging data suggest roles for OPN
in atheroma formation, for OPG in vascular calcification, and for
OCN in glucose homeostasis [65,66]. We found higher levels of
OCN in AA, in contrast with two previous reports suggesting
lower OCN levels in AA [67,68]. It is unclear how these markers
of calcification may relate to lower prevalence of osteoporosis and
coronary calcification in AA compared to NHW.
Table 6. Sex differences in women compared to men.
Both AA and NHW AA NHW
Higher Lower No difference Higher Lower No difference Higher Lower No difference
CRP TIMP-1 VCAM RAGE P-selectin Hsp27 P-selectin RAGE
SAA Lp-PLA2 activity IL-6 LDL size Hsp27 MPO Lp-PLA2 mass LDL size
ICAM CT-proAVP IL-18 ONN MPO NT-proBNP OCN ONN
ApoA-I TNFRI OCN Lp-PLA2 mass MR-proANP Factor VIII
ApoC-III TNFRII Factor VIII NT-proBNP CT-proET vWF
ApoE MCP-1 vWF MR-proANP
Lp(a) E-selectin CT-proET
Leptin MMP-2
Adiponectin MMP-9
Resistin TIMP-2
MR-proADM ApoB
OPN Ox-LDL
Factor II OPN
Factor V
Factor VII
D-dimer
ATIII
Fibrinogen
doi:10.1371/journal.pone.0009065.t006
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activities of Factors II, V, and VIII, and elevated levels of vWF, D-
dimer and fibrinogen. These ethnic differences may increase
propensity to thrombosis and contribute to higher CVD risk in AA
[47]. The process and pathways involved in hemostasis and
thrombosis are complex and have overlapping and intersecting
limbs with the overall activity governed by the balance of
activators and inhibitors.
In summary, AA ethnicity was associated with favorable levels
of inflammatory markers and Ig superfamily adhesion molecules as
well as several apolipoproteins and Lp-PLA2 mass and activity. AA
ethnicity was associated with potentially unfavorable levels of 23
markers, including inflammatory biomarkers, adipokines (leptin
and adiponectin), hemodynamic markers and markers of calcifi-
cation and thrombosis, including D-dimer and fibrinogen
(Table 7). While AA and NHW subjects were recruited from
geographically distinct locations and differed significantly in
baseline characteristics, we adjusted for both conventional and
lifestyle factors to minimize the impact of these covariates. The
differences we have identified in levels of candidate protein
markers may represent true ethnic differences in physiology and
pathophysiology and motivate further investigation.
Study Limitations
Although our study included a relatively large sample size,
multiple candidate markers, quality control measures of intra-
assay imprecision, adjustment for conventional and lifestyle factors
and the inclusion of two ethnic groups, our results will require
further validation before being applied in clinical practice. In
addition, several limitations need to be acknowledged. First,
although we measured multiple markers representative of etiologic
pathways implicated in arteriosclerotic vascular disease, other
unmeasured markers may be important in influencing risk of
disease. Second, the analytical precision of the assays varied, and
this may have influenced our results. In general, assay imprecision
reflected the robustness of the measurement technology and we
excluded data based on a quality control program as previously
detailed [13]. Multiplicity of testing with 47 biomarkers in an
individual sample also has unique statistical challenges in the
imputation of missing data and interpretation of analyses. Third,
our analysis is cross-sectional, with markers measured at only one
point in time and does not imply directionality in the associations
between markers and sex and ethnicity, notwithstanding the
biological plausibility of such associations. It is also possible that
activation of these pathways may be a consequence of arterio-
sclerosis (‘‘reverse’’ causality) and that potentially unknown
confounders and contributors were not adjusted for. AA and
NHW populations were recruited from differing geographical
locations and it is possible that unmeasured environmental and
geographic factors contributed to purported ethnic differences.
There are sparse data in the literature regarding geographic
differences in biomarker levels, although environmental differenc-
es linked to pollution exposure appear to influence circulating
levels of inflammatory markers [69,70]. Finally, the associations
described in this study may not be generalizable to younger and
normotensive adults.
Conclusions
We found significant sex and ethnic differences in circulating
levels of multiple novel candidate protein markers of CVD
independent of potential confounding variables. We performed
these analyses as a step towards identifying clinically useful panels
of for refining CVD risk assessment. The results will help guide
subsequent investigation of the association of the markers
individually and by pathway with objective measures of subclinical
vascular disease as well as with adverse cardiovascular events.
Supporting Information
Table S1 Biomarkers, Method, and Precision of Assay.
Found at: doi:10.1371/journal.pone.0009065.s001 (0.13 MB
DOC)
Table 7. African American ethnicity differences in AA compared to NHW.
Both women and men Women Men
Increased Decreased No difference Increased Decreased No difference Increased Decreased
No
difference
CRP ICAM SAA MCP-1 MR-proANP MR-proADM MR-proADM MCP-1
Hsp27 VCAM IL-6 P-selectin P-selectin
MPO IL-18 TNFRII MMP-2 MMP-2
Lp(a) TNFRI E-selectin TIMP-2 TIMP-2
Leptin RAGE ApoA-I OCN MR-proANP
CT-proAVP MMP-9 ApoE OCN
CT-proET TIMP-1 Resistin
OPN ApoB ONN
OPG ApoC-III Factor VII
Factor II LDL size ATIII
Factor V Lp-PLA2 mass
Factor VIII Lp-PLA2 activity
vWF Adiponectin
D-dimer NT-proBNP
Fibrinogen
doi:10.1371/journal.pone.0009065.t007
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